

ARTIFICIAL INTELLIGENCE-ENABLED SUSTAINABLE NANOMEDICINE: GREEN CARBON DOTS FOR SMART DRUG DELIVERY

Uttupulusu Mounika^{*1}, DR. Pashikanti Shailaja², Mangala Giri Krishna Rekha³

¹Student, Department of Pharmaceutics, AU College of Pharmaceutical Sciences, Visakhapatnam, India.

²Associate Professor, Head of the Department, Department of Pharmaceutics, AU College of Pharmaceutical Sciences, Visakhapatnam, India.

³Research Scholar, Department of Pharmaceutics, AU College of Pharmaceutical Sciences, Visakhapatnam, India.

Article Received: 07 August 2026 | Article Revised: 28 August 2026 | Article Accepted: 17 September 2026

***Corresponding Author: Uttupulusu Mounika**

Student, Department of Pharmaceutics, AU College of Pharmaceutical Sciences, Visakhapatnam, India.

DOI: <https://doi.org/10.5281/zenodo.23053307>

How to cite this Article: Uttupulusu Mounika, DR. Pashikanti Shailaja, Mangala Giri Krishna Rekha (2026) ARTIFICIAL INTELLIGENCE-ENABLED SUSTAINABLE NANOMEDICINE: GREEN CARBON DOTS FOR SMART DRUG DELIVERY. World Journal of Pharmaceutical Science and Research, 5(10), 105-121.



Copyright © 2026 Uttupulusu Mounika | World Journal of Pharmaceutical Science and Research.

This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

ABSTRACT

The rapid advancement of nanomedicine has improved drug delivery; however, conventional nanoparticle development remains limited by trial-and-error optimization, scalability constraints, and environmental concerns. Green nanotechnology offers a sustainable alternative through the use of biodegradable materials, renewable precursors, and environmentally benign synthesis approaches. Among emerging sustainable nanomaterials, green carbon dots have attracted increasing interest because of their biocompatibility, tunable surface chemistry, intrinsic fluorescence, and relatively low toxicity. Nevertheless, precise control of their physicochemical and biological properties remains challenging. Artificial intelligence (AI), particularly machine learning and data-driven modeling, provides opportunities for predictive formulation design, optimization of nanocarrier properties, and reduction of experimental burden. The integration of AI with sustainable nanomedicine therefore offers a promising strategy for developing intelligent drug delivery systems with improved therapeutic precision, targeting, controlled drug release, and bioimaging capabilities. This review critically examines the convergence of AI and sustainable nanomedicine, with particular emphasis on green carbon dots for smart drug delivery. It discusses green synthesis strategies, AI-driven nanocarrier design and optimization, intelligent targeting, controlled drug delivery, bioimaging applications, and translational challenges. Future perspectives concerning scalability, reproducibility, regulatory considerations, and environmentally responsible manufacturing are also addressed, highlighting the potential of AI-enabled green carbon dots as a sustainable platform for next-generation drug delivery.

KEYWORDS: Artificial intelligence; sustainable nanomedicine; green carbon dots; smart drug delivery; precision nanocarriers; green nanotechnology.

1. INTRODUCTION

Nanomedicine has transformed drug delivery by enabling nanoscale control over pharmacokinetics, biodistribution, and therapeutic targeting. However, despite decades of progress, the field continues to rely heavily on empirical, trial-and-error formulation strategies that are resource-intensive, environmentally burdensome, and poorly scalable. These limitations are increasingly incompatible with modern pharmaceutical expectations for sustainability, precision, and rapid translation.^[2,7]

A major challenge lies in the growing complexity of nanocarrier systems. Contemporary formulations often involve multiple interacting variables, including particle size, surface chemistry, morphology, drug loading efficiency, and biological response. Optimizing these parameters simultaneously using conventional experimental design is not only time-consuming but also generates excessive material waste and solvent consumption, directly contradicting the principles of green chemistry and sustainable development.^[14,16]

Sustainable nanomedicine has therefore emerged as a critical research priority, emphasizing biodegradable materials, renewable precursors, and environmentally benign synthesis routes. Green nanotechnology seeks to minimize ecological impact without compromising therapeutic performance, yet its adoption has been hindered by limited predictive control over material properties and *in vivo* behavior.^[1,25] In particular, carbon-based nanomaterials have gained attention due to their biocompatibility, structural tunability, and reduced long-term toxicity compared to heavy-metal-based quantum dots.^[26,28]

Among these materials, green carbon dots represent a promising class of nanocarriers synthesized from biomass, plant extracts, and biowaste through low-energy processes. Their intrinsic fluorescence, high aqueous stability, and surface functionalization flexibility make them suitable for combined drug delivery, bioimaging, and diagnostic applications. However, translating these advantages into clinically relevant systems requires precise control over synthesis conditions and functional attributes—an area where conventional approaches fall short.^[1,12]

Artificial intelligence has recently emerged as a transformative tool capable of addressing these limitations by enabling data-driven design, prediction, and optimization of nanomedicine systems. Machine learning and hybrid intelligence models can capture nonlinear relationships between formulation variables and performance outcomes, reducing experimental burden while improving reproducibility and design efficiency.^[3,11] When integrated with green nanotechnology, AI offers a pathway toward intelligent, sustainable, and application-specific drug delivery platforms.

The convergence of artificial intelligence with green nanomedicine is not merely a technological enhancement but a paradigm shift in how nanocarriers are conceived, developed, and evaluated. By combining sustainable material choices such as green carbon dots with AI-guided optimization and quality-by-digital-design frameworks, it becomes possible to accelerate innovation while aligning with environmental and regulatory expectations.^[7,8,16]

This review critically examines the emerging synergy between artificial intelligence and sustainable nanomedicine, with a focused emphasis on green carbon dots as intelligent drug delivery systems. Key advances in green synthesis, AI-driven nanoparticle design, smart targeting strategies, and translational challenges are discussed to provide a comprehensive roadmap for future research and clinical development. A comparative overview of conventional nanomedicine and AI-enabled sustainable nanomedicine is presented in **Table 1**.

Table 1: Comparison between conventional nanomedicine and AI-enabled sustainable nanomedicine.

Aspect	Conventional Nanomedicine	AI-Enabled Sustainable Nanomedicine
Design strategy	Trial-and-error based	Data-driven and predictive
Optimization	Time-consuming, empirical	Rapid multi-parameter optimization
Material selection	Often synthetic, non-renewable	Bio-derived and green materials
Environmental impact	High solvent and energy use	Reduced waste and energy consumption
Reproducibility	Batch-to-batch variability	Improved consistency via AI control
Scalability	Difficult and unpredictable	Digitally guided and scalable
Clinical translation	Slow	Accelerated

2. GREEN NANOTECHNOLOGY IN DRUG DELIVERY

2.1 Principles of Green Nanotechnology

The growing emphasis on sustainability in pharmaceutical sciences has driven the adoption of green nanotechnology as an alternative to conventional nanocarrier development. Traditional nanoparticle synthesis often relies on toxic solvents, energy-intensive processes, and non-biodegradable materials, leading to environmental burden and regulatory challenges. In contrast, green nanotechnology prioritizes renewable resources, low-energy fabrication routes, and safer chemical inputs while maintaining functional performance in drug delivery applications.^[14,16]

2.2 Sustainable Materials for Drug Delivery Applications

At the material level, green nanocarriers are typically derived from biodegradable polymers, natural biomolecules, or carbon-based systems obtained from plant, microbial, or waste-derived sources. These materials reduce long-term bioaccumulation risks and improve biological compatibility, addressing toxicity concerns that have limited the clinical translation of several inorganic nanomaterials. For example, biodegradable polymeric nanoparticles and bio-derived carbon nanostructures demonstrate improved clearance profiles and reduced inflammatory responses compared to heavy-metal-containing systems.^[25,26]

2.3 Green Synthesis Approaches and Environmental Benefits

From a process perspective, green synthesis strategies emphasize solvent minimization, aqueous-based reactions, and ambient reaction conditions. Methods such as hydrothermal treatment of biomass, microwave-assisted synthesis, and enzyme-mediated fabrication have enabled the production of functional nanocarriers with reduced chemical waste and energy consumption. These approaches align with the principles of green chemistry while offering scalability potential for pharmaceutical manufacturing.^[28,30] However, variability in raw biological precursors often leads to batch-to-batch inconsistency, which remains a critical limitation of purely green approaches.

2.4 Functional Advantages and Current Limitations

Functionally, green nanotechnology has expanded beyond environmental considerations to actively enhance therapeutic performance. Sustainable nanocarriers are increasingly designed to support multifunctionality, including drug loading, controlled release, targeting, and diagnostic capability. Carbon-based green nanomaterials, in particular, exhibit favorable surface chemistry that allows facile functionalization with ligands, polymers, or biomolecules, enabling responsive and targeted drug delivery without introducing toxic components.^[1,12]

Despite these advances, green nanotechnology alone does not fully resolve the complexity associated with nanocarrier optimization. The high dimensionality of formulation variables—such as precursor composition, reaction conditions, surface functional groups, and biological interactions—makes rational design challenging. This limitation has slowed

the translation of sustainable nanocarriers into clinically viable products, underscoring the need for intelligent, predictive frameworks capable of guiding green nanomaterial development.^[7,11]

Consequently, the integration of artificial intelligence with green nanotechnology has emerged as a strategic solution to overcome reproducibility, scalability, and performance trade-offs. By combining environmentally responsible material choices with data-driven optimization, green nanotechnology can transition from a sustainability-driven concept to a precision-engineered platform for next-generation drug delivery systems.^[2,8]




Fig. 1: Conceptual overview of green nanotechnology in drug delivery illustrating sustainable material selection, environmentally benign synthesis routes, and functional nanocarrier design for controlled and targeted therapeutic delivery. The framework highlights the transition from conventional, resource-intensive nanoparticle fabrication to eco-friendly and biodegradable nanomedicine platforms.

3. GREEN CARBON DOTS: PROPERTIES AND BIOMEDICAL RELEVANCE

3.1 Sustainable Sources and Green Synthesis of Carbon Dots

Green carbon dots have emerged as a distinct class of sustainable nanomaterials that address both functional and environmental limitations associated with conventional nanocarriers. Unlike traditional semiconductor quantum dots, which often rely on toxic heavy metals and harsh synthesis conditions, green carbon dots are typically produced from renewable biological precursors such as plant extracts, agricultural waste, and food byproducts using low-energy, solvent-minimized processes.^[25,26] This combination of material safety and sustainable fabrication has positioned them as attractive candidates for next-generation drug delivery and diagnostic platforms.

3.2 Physicochemical Properties and Surface Characteristics

From a physicochemical perspective, green carbon dots exhibit nanoscale dimensions, high aqueous dispersibility, and rich surface chemistry dominated by oxygen- and nitrogen-containing functional groups. These features enable efficient drug loading through electrostatic interactions, hydrogen bonding, or covalent conjugation, while also supporting surface modification with targeting ligands or polymers. Two practical examples illustrate this advantage: first, biowaste-derived carbon dots functionalized with amino groups have demonstrated improved drug encapsulation efficiency for hydrophilic therapeutics; second, plant-based carbon dots modified with polyethylene glycol have shown enhanced colloidal stability and prolonged systemic circulation.^[1,12]

3.3 Drug Loading, Controlled Release, and Imaging Capability

A defining characteristic of carbon dots is their intrinsic photoluminescence, which allows simultaneous therapeutic delivery and real-time bioimaging without the need for additional fluorescent labels. This dual functionality supports image-guided drug delivery and theranostic applications, where treatment response can be monitored dynamically. For

instance, fluorescent carbon dots loaded with anticancer agents have enabled visualization of cellular uptake and intracellular drug release, while similar systems have been applied for tracking ocular and transdermal drug distribution in preclinical models.^[12,28]

3.4 Biocompatibility and Safety Profile

Biological compatibility is another critical advantage of green carbon dots. Their carbon-based composition and absence of heavy metals significantly reduce cytotoxicity and long-term accumulation risks. Studies have consistently reported low hemolytic activity, minimal inflammatory response, and favorable clearance profiles compared to metal-based nanomaterials. Two contrasting examples highlight this benefit: metal quantum dots often exhibit dose-dependent oxidative stress and organ retention, whereas green carbon dots derived from natural precursors demonstrate improved safety margins even at higher concentrations.^[26,30]

Table 2: Key properties of green carbon dots relevant to drug delivery.

Property	Description	Relevance to Drug Delivery
Source	Biomass, plant extracts, biowaste	Sustainable and eco-friendly
Particle size	<10 nm	Enhanced tissue penetration
Surface functional groups	–OH, –COOH, –NH ₂	Efficient drug loading and targeting
Photoluminescence	Intrinsic fluorescence	Bioimaging and tracking
Biocompatibility	Low toxicity	Improved safety
Stability	High aqueous stability	Reliable formulation performance

3.5 Reproducibility Challenges and Need for AI Integration

Despite these strengths, the performance of green carbon dots is highly sensitive to synthesis conditions, including precursor composition, reaction temperature, and surface passivation strategies. Small variations in these parameters can result in significant changes in size distribution, fluorescence intensity, and biological interaction. This intrinsic variability poses challenges for reproducibility and clinical translation, particularly when green synthesis routes rely on heterogeneous biological feedstocks.^[1,29]

Consequently, while green carbon dots provide an environmentally responsible and multifunctional platform for drug delivery, their full potential can only be realized through precise control and predictive optimization. This limitation underscores the need for artificial intelligence-driven approaches capable of correlating synthesis parameters with functional outcomes, thereby enabling rational design of carbon-dot-based nanomedicine systems.^[3,11]




Fig. 2: Schematic illustration of green carbon dots highlighting sustainable synthesis from bio-derived precursors, key physicochemical properties, and their biomedical relevance in drug delivery, bioimaging, and theranostic applications.

4. ROLE OF ARTIFICIAL INTELLIGENCE IN NANOCARRIER DESIGN

4.1 AI-Based Prediction of Nanocarrier Properties

The design of nanocarriers for drug delivery involves the simultaneous optimization of multiple interdependent parameters, including particle size, surface charge, morphology, drug loading efficiency, release kinetics, and biological interactions. Conventional experimental approaches struggle to address this complexity efficiently, often requiring extensive trial-and-error experimentation with limited predictive capability. Artificial intelligence has emerged as a powerful solution by enabling data-driven modeling and optimization of nanocarrier systems beyond the capacity of traditional design frameworks.^[3,11]

4.2 Machine Learning for Formulation Optimization

Machine learning algorithms can identify nonlinear relationships between formulation variables and performance outcomes using experimental and computational datasets. Supervised learning models, such as artificial neural networks and support vector machines, have been applied to predict nanoparticle characteristics based on synthesis parameters. For example, machine learning models have successfully predicted optimal polymer-to-drug ratios and solvent conditions for biodegradable nanoparticles, while similar approaches have been used to forecast particle size and encapsulation efficiency in carbon-based nanocarriers.^[4,6] These predictive capabilities significantly reduce experimental burden and material waste.

4.3 AI-Driven Rational Design and Smart Nanocarriers

Beyond prediction, artificial intelligence facilitates rational nanocarrier design through optimization and decision-making frameworks. Hybrid intelligence models and kernel-based learning systems enable multi-objective optimization, balancing therapeutic efficacy, stability, and safety simultaneously. Two practical outcomes of such approaches include the identification of synthesis conditions that maximize drug loading without increasing cytotoxicity, and the selection of surface functionalization strategies that enhance cellular uptake while minimizing off-target effects.^[5,20]

AI-driven design has also enabled the development of smart and responsive nanocarriers capable of adapting to biological stimuli. By integrating biological data with formulation parameters, machine learning models support the design of nanoparticles that respond to pH, enzymes, or redox environments for controlled drug release. These intelligent systems have shown promise in applications such as tumor-targeted therapy and organ-specific delivery, where conventional formulations often fail to achieve adequate precision.^[9,22] Major applications of artificial intelligence in nanocarrier design and optimization are outlined in **Table 3**.

Table 3: Applications of artificial intelligence in nanocarrier design.

AI Application	Function	Outcome
Property prediction	Predict size and charge	Reduced experimental trials
Formulation optimization	Multi-variable tuning	Higher encapsulation efficiency
Targeting prediction	Ligand–receptor analysis	Improved tissue specificity
Release modeling	Controlled release prediction	Enhanced therapeutic efficacy
Toxicity prediction	Safety profiling	Early risk identification

4.4 Limitations and Data Dependency of AI Models

Despite these advantages, the application of artificial intelligence in nanocarrier design faces notable challenges. The reliability of AI models depends heavily on data quality, diversity, and interpretability. Limited datasets, experimental

bias, and lack of standardized reporting can compromise model generalizability and hinder regulatory acceptance. Addressing these challenges requires the integration of explainable AI, standardized data generation, and validation strategies aligned with pharmaceutical quality frameworks.^[7,32]

Overall, artificial intelligence represents a transformative tool in nanocarrier design, shifting formulation development from empirical experimentation to predictive and optimized engineering. When combined with sustainable nanomaterials such as green carbon dots, AI-driven approaches offer a robust pathway toward intelligent, scalable, and environmentally responsible drug delivery systems.^[8,16]

5. AI-Driven Smart and Targeted Drug Delivery Systems

5.1 AI-Assisted Targeted Drug Delivery

Smart and targeted drug delivery systems aim to deliver therapeutic agents selectively to diseased tissues while minimizing systemic exposure and adverse effects. Achieving this level of precision requires an integrated understanding of nanocarrier properties, biological barriers, and patient-specific variability—an objective that exceeds the capabilities of conventional formulation strategies. Artificial intelligence has become central to overcoming these limitations by enabling predictive targeting, adaptive delivery design, and personalization of nanomedicine platforms.^[5,8]

AI-driven models have been widely applied to optimize targeting efficiency by correlating nanoparticle physicochemical properties with biological outcomes such as cellular uptake, biodistribution, and organ accumulation. Machine learning approaches can analyze large datasets derived from in vitro, in vivo, and imaging studies to identify optimal size ranges, surface charges, and ligand densities for specific therapeutic targets. For example, AI-guided optimization has improved tumor-targeting efficiency by predicting ligand–receptor interactions, while similar models have enhanced cardiovascular and ocular drug delivery by tailoring nanocarrier surface properties to tissue-specific barriers.^[22,23]

5.2 Stimuli-Responsive and Smart Drug Delivery

Stimuli-responsive drug delivery represents another area where artificial intelligence has demonstrated significant impact. Smart nanocarriers designed to respond to internal triggers such as pH, enzymatic activity, or redox gradients can release drugs selectively at pathological sites. AI algorithms assist in selecting material compositions and functional groups that maximize responsiveness while maintaining stability under physiological conditions. Two concrete examples include pH-responsive nanocarriers optimized for tumor microenvironments and enzyme-sensitive systems designed for site-specific drug release in inflammatory diseases.^[9,19]

Table 4: Role of AI in smart and targeted drug delivery systems.

Drug Delivery Strategy	AI Contribution	Therapeutic Benefit
Targeted delivery	Optimization of surface ligands	Reduced off-target toxicity
Stimuli-responsive systems	Trigger sensitivity prediction	Site-specific drug release
Personalized delivery	Patient-data integration	Precision therapy
Image-guided delivery	Multimodal data analysis	Real-time monitoring

5.3 Personalized Drug Delivery and Precision Medicine

Personalized drug delivery is an emerging outcome of AI-driven nanomedicine, where formulation design is adapted to individual patient characteristics. By integrating clinical, genetic, and pharmacokinetic data, artificial intelligence

enables the prediction of patient-specific nanocarrier behavior and therapeutic response. Such approaches have been explored in precision oncology and phytomedicine-based therapies, where variability in drug metabolism and disease progression necessitates tailored delivery strategies.^[10,22] This shift from population-based to individualized nanocarrier design marks a critical advancement in precision healthcare.

5.4 Integration of Green Carbon Dots in Smart Delivery

Green carbon dots further enhance the feasibility of AI-driven smart delivery due to their tunable surface chemistry and intrinsic imaging capability. AI-assisted optimization of carbon-dot-based systems has facilitated the development of multifunctional platforms capable of simultaneous targeting, drug release, and real-time tracking. For instance, machine learning models have been used to optimize surface functionalization of carbon dots for enhanced cellular uptake, while maintaining low toxicity and environmental sustainability.^[1,12]

Despite these advances, challenges remain in translating AI-driven smart delivery systems into clinical practice. Model interpretability, regulatory validation, and integration of heterogeneous biological data remain unresolved issues. Addressing these barriers requires standardized datasets, explainable AI frameworks, and close alignment with regulatory quality expectations to ensure safety, reliability, and reproducibility.^[16,24]




Fig. 3: Conceptual representation of AI-driven smart and targeted drug delivery systems illustrating data-guided nanocarrier design, optimization of physicochemical properties, and stimuli-responsive drug release.

6. QUALITY BY DIGITAL DESIGN AND SUSTAINABLE SCALE-UP OF NANOMEDICINE

6.1 Concept of Quality by Digital Design

One of the primary barriers to the clinical translation of nanomedicine is the lack of reproducibility and scalability in nanoparticle manufacturing. While laboratory-scale formulations often demonstrate promising therapeutic outcomes, many fail during scale-up due to variability in material properties, process sensitivity, and inadequate quality control. Quality by Digital Design (QbDD) has emerged as an advanced framework that integrates artificial intelligence, process modeling, and quality-by-design principles to address these challenges systematically.^[7,31]

6.2 AI-Guided Process Optimization

QbDD extends conventional quality-by-design by incorporating real-time data analytics, machine learning, and predictive modeling to guide formulation and process decisions. Instead of relying solely on predefined experimental spaces, AI-driven digital models continuously learn from experimental and process data to identify critical quality attributes and critical process parameters. For example, machine learning models have been used to predict nanoparticle size distribution and drug encapsulation efficiency during scale-up, while adaptive optimization algorithms have enabled consistent batch-to-batch performance in polymeric and carbon-based nanocarriers.^[18,20] Key elements of the quality by digital design framework and their role in sustainable nanomedicine development are presented in Table 5.

Table 5: Key elements of quality by digital design for sustainable nanomedicine.

QbDD Component	Role	Impact
Critical quality attributes	Define performance standards	Improved reproducibility
Machine learning models	Predict process outcomes	Reduced waste
Digital twins	Simulate manufacturing	Energy-efficient scale-up
Real-time monitoring	Continuous quality control	Lower batch failure
Lifecycle assessment	Environmental evaluation	Regulatory compliance

Sustainable scale-up is a central advantage of QbDD-enabled nanomedicine development. AI-assisted process optimization reduces excessive solvent usage, energy consumption, and raw material waste by identifying optimal operating windows early in development. Two concrete examples illustrate this benefit: first, digital optimization of supercritical fluid-based nanoparticle production has improved solubility enhancement while minimizing solvent residue; second, AI-guided control of reaction parameters in green nanomaterial synthesis has improved yield consistency without increasing environmental burden.^[18,30]

6.3 Digital Twins and Sustainable Manufacturing

Digital twins—virtual representations of physical manufacturing processes—play a critical role in quality-by-digital-design strategies. These models simulate nanoparticle synthesis, purification, and formulation processes under varying conditions, allowing rapid assessment of process robustness and failure risk. In nanomedicine manufacturing, digital twins have enabled proactive identification of scale-dependent instabilities and supported regulatory documentation by providing transparent, data-backed process understanding.^[7,31]

For sustainable nanocarriers such as green carbon dots, QbDD frameworks are particularly valuable due to the inherent variability of bio-derived precursors. AI-driven normalization and adaptive control strategies can compensate for differences in precursor composition, ensuring consistent physicochemical properties and biological performance. This capability is essential for translating green synthesis approaches from academic settings to industrial and clinical production.^[1,16]

6.4 Regulatory and Translational Considerations

Despite its promise, the implementation of QbDD in nanomedicine faces challenges related to data standardization, model validation, and regulatory acceptance of AI-driven decisions. Regulatory agencies increasingly recognize the value of digital tools, but clear guidelines for AI-integrated manufacturing are still evolving. Addressing these challenges will require transparent model architectures, explainable AI, and close alignment with pharmaceutical quality systems to ensure trust and compliance.^[32,33]

Overall, quality by digital design represents a critical enabler for the sustainable and scalable development of AI-driven nanomedicine. By unifying green material selection, intelligent process control, and predictive quality management, QbDD provides a practical pathway for translating innovative nanocarrier systems from the laboratory to clinical application while maintaining environmental and regulatory integrity.^[7,16]




Fig. 4: Quality-by-design framework for nanomedicine illustrating the application of predictive modeling to nanomedicine development, including optimization of formulation parameters, prediction of physicochemical properties, biological activity and toxicity, targeted nanomedicine design, environmental risk assessment, and scale-up from laboratory to industrial manufacturing.

7. CHALLENGES, ETHICAL CONSIDERATIONS, AND AI BIAS IN SUSTAINABLE NANOMEDICINE

7.1 Data Bias and Model Generalizability

Despite rapid advances, the integration of artificial intelligence with sustainable nanomedicine presents significant scientific, ethical, and regulatory challenges that must be addressed before widespread clinical adoption. One of the most persistent issues is **data dependency**. AI models used for nanocarrier design rely heavily on experimental datasets that are often limited in size, biased toward successful formulations, or generated under non-standardized conditions. As a result, model predictions may lack robustness when applied to new materials, biological systems, or patient populations.^[16,24]

AI bias represents a particularly serious concern in nanomedicine development. When training datasets disproportionately represent specific materials, disease models, or biological conditions, the resulting algorithms may favor certain design pathways while overlooking viable alternatives. For example, AI models trained predominantly on polymeric nanoparticles may perform poorly when applied to carbon-based nanocarriers such as green carbon dots. Similarly, predictive models optimized for oncology applications may fail to generalize to ocular, cardiovascular, or neurological drug delivery systems.^[11,19] These biases can slow innovation and introduce hidden risks in translational research.

7.2 Interpretability and Transparency Issues

Another challenge lies in **model interpretability and transparency**. Many high-performing AI approaches, particularly deep learning architectures, operate as “black boxes,” making it difficult to explain how specific formulation decisions are derived. In pharmaceutical development, where regulatory approval depends on mechanistic

understanding and reproducibility, this lack of explainability poses a major obstacle. Explainable AI frameworks and hybrid modeling approaches are increasingly being explored to balance predictive accuracy with interpretability, but their adoption remains limited.^[32,33]

7.3 Nanotoxicology and Safety Challenges

Nanotoxicology and long-term safety assessment further complicate AI-driven nanomedicine design. While machine learning models have been applied to predict cytotoxicity, biodistribution, and organ accumulation, these predictions are constrained by incomplete biological data and short-term experimental endpoints. For sustainable nanomaterials such as green carbon dots, long-term environmental fate and chronic exposure effects are still poorly understood. AI-based toxicological predictions must therefore be complemented by experimental validation to avoid false assurances of safety.^[26,32] Major challenges and future directions associated with AI-enabled sustainable nanomedicine are summarized in Table 6.

Table 6: Challenges and future directions in AI-enabled sustainable nanomedicine.

Challenge	Limitation	Future Direction
Data bias	Poor generalization	Diverse standardized datasets
Model interpretability	Black-box AI	Explainable AI models
Nanotoxicology	Limited long-term data	AI-assisted safety modelling
Scale-up	Process variability	Digital twin-based manufacturing
Regulatory acceptance	Lack of clear AI guidelines	AI-specific regulatory frameworks

7.4 Ethical and Regulatory Concerns

Ethical considerations also arise from the increasing use of patient-specific data in AI-enabled personalized nanomedicine. The integration of clinical, genetic, and pharmacokinetic datasets raises concerns regarding data privacy, ownership, and informed consent. Without clear governance frameworks, the use of AI in precision drug delivery risks undermining public trust and slowing regulatory acceptance.^[33,35]

Finally, regulatory frameworks have yet to fully adapt to AI-driven and digitally optimized nanomedicine systems. While regulatory agencies acknowledge the potential of AI-assisted design and quality control, standardized guidelines for validation, auditability, and lifecycle management of AI models remain under development. Bridging this regulatory gap is essential to ensure that AI-enabled sustainable nanomedicine progresses from academic innovation to clinical reality.^[7,16]




Fig. 5: Key challenges and ethical considerations associated with AI-enabled sustainable nanomedicine, including data bias, model interpretability, nanotoxicological uncertainty, regulatory adaptation, and patient data governance. Addressing these challenges is essential for the safe, transparent, and clinically translatable implementation of intelligent nanomedicine platforms.

8. FUTURE PERSPECTIVES AND RESEARCH ROADMAP

8.1 Explainable and Hybrid AI Models

The future of sustainable nanomedicine will be shaped by how effectively artificial intelligence is integrated with green material science, regulatory frameworks, and clinical translation pathways. Moving forward, the emphasis must shift from proof-of-concept demonstrations to **robust, explainable, and translatable AI-enabled nanocarrier systems**. Without this shift, AI risks remaining an academic optimization tool rather than a clinically impactful technology.^[15,16]

One critical direction is the development of **explainable and hybrid AI models** tailored for nanomedicine. Rather than relying exclusively on deep learning architectures, future frameworks are expected to combine mechanistic modeling with data-driven learning. Two concrete advances illustrate this trajectory: first, hybrid physics-informed machine learning models that incorporate nanoparticle transport and interaction mechanisms; second, adaptive learning systems that update predictions as new experimental or clinical data become available. These approaches improve trust, reproducibility, and regulatory acceptability.^[6,31]

8.2 AI-Enabled Personalized Green Nanocarriers

Another major opportunity lies in the **convergence of green carbon dots with precision and personalized medicine**. AI-guided optimization can enable patient- or disease-specific tuning of carbon dot size, surface chemistry, and drug-loading profiles. This is particularly relevant in areas such as oncology, neurological disorders, and ocular drug delivery, where inter-patient variability strongly influences therapeutic outcomes. AI-enabled personalization transforms green carbon dots from generic nanocarriers into adaptive therapeutic platforms.^[10,19,22]

8.3 Digital Manufacturing and Lifecycle Assessment

From a manufacturing perspective, the expansion of **digital twins and real-time AI control** will play a decisive role in sustainable scale-up. Future nanomedicine production lines are likely to integrate continuous monitoring, predictive maintenance, and automated quality control driven by machine learning. Two practical benefits are anticipated: reduced batch failure rates and lower environmental footprint through optimized energy and solvent usage. These advances directly align with global sustainability goals and evolving regulatory expectations.^[7,18]

The integration of AI into **nanotoxicology and lifecycle assessment** also represents a critical research frontier. Predictive models capable of assessing long-term biological and environmental impacts of nanomaterials—particularly bio-derived systems such as green carbon dots—will be essential for responsible innovation. Coupling AI-based toxicity prediction with experimental validation and post-market surveillance will strengthen safety assurance and public confidence.^[26,32]

8.4 Translational and Clinical Outlook

Finally, interdisciplinary collaboration will determine the success of AI-enabled sustainable nanomedicine. Progress will require coordinated efforts among material scientists, data scientists, clinicians, regulatory bodies, and industry

stakeholders. Establishing standardized datasets, shared modeling frameworks, and transparent validation protocols will be key to accelerating translation while maintaining ethical and environmental integrity.^[33–35]




Fig. 6: Future research roadmap for AI-enabled sustainable nanomedicine highlighting explainable artificial intelligence, personalized nanocarrier design, digital manufacturing frameworks, and integrated safety assessment for clinically translatable green nanomedicine systems.

9. CASE STUDIES IN AI-ENABLED GREEN NANOFORMULATIONS: STRUCTURED REVIEW ANALYSIS

Case Study 1: AI-Guided TuNa-AI Platform for Sustainable Cancer Nanoparticle Design

Recent advances in artificial intelligence have enabled the rational design of cancer nanocarriers that overcome the inefficiencies of empirical formulation strategies. One prominent example is the TuNa-AI platform developed at Duke University, which integrates automated experimentation with hybrid kernel-based machine learning to design biodegradable nanoparticles under explicit sustainability constraints.^[36]

Conventional nanoparticle formulation for hydrophobic anticancer agents is typically resource-intensive, poorly reproducible, and highly dependent on toxic organic solvents and excipients. These limitations are particularly evident in formulations developed for drugs such as venetoclax, where solubility and stability challenges often necessitate environmentally harmful processing routes.^[36,37]

The TuNa-AI framework addressed these issues by employing hybrid kernel learning models capable of predicting optimal excipient ratios, polymer compositions, and synthesis conditions while minimizing experimental iterations and solvent toxicity. Importantly, sustainability constraints were embedded directly into the optimization objective, aligning nanoparticle development with green chemistry principles rather than treating sustainability as an afterthought. As a result, AI-guided optimization led to a marked increase in successful nanoparticle fabrication rates, a substantial reduction in toxic excipient usage, and significantly lower experimental waste. Preclinical evaluation in leukemia mouse models further demonstrated improved drug solubility and biodistribution, highlighting both therapeutic and environmental benefits.^[36] From a clinical perspective, this case study illustrates how AI-enabled formulation platforms can support scalable, low-toxicity nanoparticle development for precision oncology while simultaneously reducing environmental burden and improving reproducibility.

Case Study 2: AI-Optimized Green Carbon Dots for Doxorubicin Theranostics

Green carbon dots have emerged as a promising alternative to heavy-metal-based quantum dots due to their biodegradability, low toxicity, and sustainable synthesis routes. However, tailoring their physicochemical properties for combined drug delivery and imaging remains challenging without predictive design tools. This challenge has been addressed through the integration of machine learning-based optimization strategies.^[38–40] In this case study, biomass-derived green carbon dots were optimized using supervised machine learning models, including support vector regression and deep learning, to enhance doxorubicin loading, surface functionalization, and pH-responsive drug release. The motivation stemmed from the cardiotoxicity and nonspecific biodistribution associated with doxorubicin, as well as the sustainability concerns linked to conventional quantum dots.^[38,39] AI-driven optimization enabled the identification of precursor compositions and surface chemistries that achieved high encapsulation efficiency and selective drug release under acidic tumor-like conditions. Functionalization with targeting ligands further enhanced tumor-specific uptake while preserving the intrinsic fluorescence of the carbon dots, allowing real-time imaging of drug distribution.^[38–40]

Biological evaluation in cancer cell models demonstrated reduced cytotoxicity toward non-target cells, enhanced tumor uptake, and effective fluorescence-guided monitoring. This case study establishes AI-optimized green carbon dots as viable nanotheranostic platforms that combine therapeutic efficacy, imaging capability, and environmental responsibility.^[39,40]

Case Study 3: Generative AI for Targeted Nanoparticles in Ovarian Cancer Therapy

Generative artificial intelligence has expanded the design space for nanoparticle-based drug delivery by enabling *in silico* exploration of formulation parameters that would be prohibitively expensive to test experimentally. A notable application of this approach was reported by Insilico Medicine in the context of ovarian cancer nanotherapy.^[41,42]

Ovarian cancer presents substantial delivery challenges due to biological barriers, immunosuppressive tumor microenvironments, and limited responsiveness to standard therapies. Experimental optimization of nanoparticles for such complex systems is costly and inefficient, particularly when targeting genetically defined subpopulations such as BRCA-deficient tumors. Using generative AI platforms, nanoparticle size, surface PEGylation, biodegradable composition, and stimuli-responsive release characteristics were optimized for the delivery of Polθ inhibitors and immunomodulatory agents such as interleukin-12. This AI-driven design process significantly reduced experimental iterations while prioritizing biocompatibility and material efficiency.^[41,42] Preclinical studies demonstrated pronounced tumor regression, increased intratumoral T-cell infiltration, and reduced off-target toxicity compared to conventionally optimized formulations. Beyond therapeutic gains, the approach substantially lowered material usage and experimental waste, reinforcing the sustainability advantages of generative AI-enabled nanoformulation.^[42]

Case Study 4: AI-Optimized Lipid Nanoparticles for mRNA Vaccine Delivery

The successful deployment of mRNA vaccines during the COVID-19 pandemic provided one of the most visible demonstrations of AI-assisted nanoformulation at clinical scale. AI-guided lipid nanoparticle optimization played a critical role in improving mRNA stability, delivery efficiency, and manufacturability in vaccines developed by Moderna.^[43,44] mRNA therapeutics face intrinsic challenges related to instability, immune recognition, and inefficient cellular uptake, compounded by sustainability concerns associated with solvent-intensive lipid synthesis. Machine learning models were employed to optimize ionizable lipid composition, charge behavior, and self-assembly dynamics

while favoring physiologically compatible lipids and lower-energy processing routes.^[43] AI-optimized lipid nanoparticles exhibited high encapsulation efficiency, enhanced cellular uptake, and improved endosomal escape, enabling dose reduction without compromising efficacy. These improvements contributed to high clinical efficacy while supporting scalable manufacturing with reduced solvent usage and material waste.^[43,44] This case study validates AI-enabled green nanoformulation as a robust platform not only for vaccines but also for broader gene therapy and rapid-response therapeutic development.

Integrative Perspective

Taken together, these case studies demonstrate that AI-enabled green nanoformulations consistently achieve three converging outcomes: enhanced therapeutic performance, reduced toxicity and environmental impact, and accelerated, more reproducible development pipelines. Across oncology, theranostics, targeted therapy, and vaccines, AI-driven sustainable nanoformulation has progressed beyond experimental proof-of-concept and now represents a clinically relevant, regulatory-compatible pathway for next-generation drug delivery and precision healthcare.^[36–44]

CONCLUSION

Artificial intelligence-enabled sustainable nanomedicine represents a transformative shift in drug delivery research, moving the field beyond empirical formulation toward predictive, efficient, and environmentally responsible design. Green carbon dots exemplify this transition by combining renewable sourcing, biocompatibility, and multifunctionality with the potential for intelligent optimization. Throughout this review, the convergence of green nanotechnology and artificial intelligence has been shown to address key limitations in conventional nanomedicine, including inefficiency, poor reproducibility, and environmental burden. AI-driven approaches enable rational nanocarrier design, smart targeting, and quality-by-digital-design frameworks that support scalable and regulatory-aligned development. When applied to green carbon dots, these tools unlock advanced capabilities in controlled drug delivery, bioimaging, and precision therapy.

Nevertheless, the successful translation of AI-enabled sustainable nanomedicine will depend on overcoming challenges related to data quality, model interpretability, nanotoxicological uncertainty, and regulatory acceptance. Addressing these issues requires explainable AI, standardized validation strategies, and ethical governance of data-driven systems. In conclusion, the integration of artificial intelligence with green carbon-dot-based nanomedicine offers a compelling pathway toward intelligent, sustainable, and patient-centered drug delivery. Continued interdisciplinary collaboration and responsible innovation will be essential to realize the full clinical and societal impact of this emerging paradigm.

REFERENCES

1. Sezer Karnak E, Ulucan Karnak F, Akgöl S. Green carbon dots in the era of AI: sustainable synthesis, intelligent drug delivery, advanced diagnostics, and bioimaging. *Turk J Biol*, 2025; 49(5): 498–533. PMID: 41246234.
2. A review of artificial intelligence (AI)-driven smart and sustainable drug delivery systems: a dual-framework roadmap for the next pharmaceutical paradigm. *ChemEngineering*, 2025; 7(4): 179. Doi:10.3390/chemengineering7040179.
3. Kapoor DU, Sharma JB, Gandhi SM. AI-driven design and optimization of nanoparticle-based drug delivery systems. *Sci Eng Health Stud*, 2024; 18: 1–13. Doi:10.14456/sehs.2024.264345.
4. Almansour A, Alqahtani M. Utilization of machine learning approach for production of optimized PLGA nanoparticles for drug delivery applications. *Sci Rep*, 2025; 15: 92725. Doi:10.1038/s41598-025-92725-y.

5. Bae KH, Wang Y, Lee S, et al. Artificial intelligence-driven nanoarchitectonics for smart targeted drug delivery. *Adv Mater*, 2025; e2510239. Doi:10.1002/adma.202510239.
6. TuNa-AI Consortium. TuNa-AI: a hybrid kernel machine to design tunable nanoparticles for drug delivery. *ACS Nano*, 2025. Doi:10.1021/acsnano.5c09066.
7. Quality by digital design for accelerated sustainable nanomedicine development. *Eur J Pharm Sci*, 2025; 106886. Doi: 10.1016/j.ejps.2025.106886.
8. Impact of bridging the gap between artificial intelligence and nanomedicine in healthcare. *Sustain Chem Pharm*, 2025; 101072. Doi: 10.1016/j.scp.2025.101072.
9. Sustainable nanotechnology and artificial intelligence to empower image-guided therapy for precision healthcare. *BME Frontiers*, 2025. Doi:10.34133/bmef.0150.
10. Artificial intelligence in predicting personalized nanocarrier formulations for herbal drugs: bridging phytomedicine and precision nanotechnology. *Sustain Chem Pharm*, 2025; 101050. Doi: 10.1016/j.scp.2025.101050.
11. Nanomaterials in drug delivery: leveraging artificial intelligence and big data for predictive design. *Int J Mol Sci*, 2025; 26(22): 11121. Doi:10.3390/ijms262211121.
12. Applications of green carbon dots in personalized diagnostics for precision medicine. *Int J Mol Sci*, 2025; 26(7): 2846. Doi:10.3390/ijms26072846.
13. Artificial intelligence: a catalyst for breakthroughs in nanotechnology and pharmaceutical research. *Int J Pharm Sci Nanotechnol*, 2025.
14. Green nanocarriers and biodegradable systems for sustainable pharmaceutical delivery. *Drug Invent Today*, 2025.
15. Synergizing sustainable green nanotechnology and AI/ML for advanced drug delivery. In: Elsevier Book Chapter. Elsevier, 2025.
16. Nano-AI synergy: emerging trends, applications, challenges, and future perspectives. *Sustain Chem Pharm*, 2025.
17. Machine learning-driven advances in nanotechnology: from materials design to process optimization. *Mater Today Commun*, 2025.
18. Computational intelligence modeling and optimization of small molecule API solubility in supercritical solvent for production of drug nanoparticles. *Sci Rep*, 2025.
19. Artificial intelligence-based advancements in nanomedicine for brain disorder management: an updated narrative review. *Front Med (Lausanne)*, 2025.
20. Advanced hybrid intelligence evaluation of nanomedicine delivery to various organs using machine learning and adaptive tree-structured Parzen estimator. *Sci Rep*, 2025.
21. Nanotechnology and machine learning synergies for improving the delivery of dietary polyphenols. *Food Res Int*, 2025.
22. Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology. *AIMS Bioeng*, 2025.
23. Artificial intelligence nanoparticle-based drug delivery systems and targeted delivery of therapeutics for the treatment of cardiovascular diseases: a systematic review. *Front Pharmacol*, 2025.
24. A review of emerging trends in nanomaterial-driven AI for biomedical applications. *Nanoscale Adv*, 2025.
25. Carbon dots: synthesis, characterizations, and recent advancements in biomedical, optoelectronics, sensing, and catalysis applications. *ACS Appl Bio Mater*, 2025.
26. Review of green synthesized carbon dots: applications in pharmaceutical drug sensing. *Carbon Trends*, 2025.

27. Emerging trends in green carbon dots coated with molecularly imprinted polymers for sensor platforms. *Trends Anal Chem*, 2025.
28. Recent progress in biowaste-derived carbon dots for cancer theranostics toward a green solution to toxic metal quantum dots. *Discov Nano*, 2025.
29. Protocol for green synthesis of excellent fluorescent mango leaves-derived carbon for advanced theragnostic in biological applications. *bioRxiv*, 2025.
30. Green synthesis of quantum dots for sustainable drug delivery. Hershey (PA): IGI Global, 2025.
31. Artificial intelligence-enhanced nanomedicine design and deep reinforcement learning in pharmacokinetics. Hershey (PA): IGI Global, 2025.
32. Artificial intelligence and machine learning in computational nanotoxicology: unlocking and empowering nanomedicine. *Adv Healthc Mater*, 2025.
33. Revolutionizing drug delivery: the role of artificial intelligence in nanomedicine and precision pharma. Springer Nature, 2025.
34. Creating new drug delivery techniques with AI. *Duke Today / Research News*, 2025.
35. Artificial intelligence and machine learning in computational nanotoxicology: unlocking and empowering nanomedicine. *Adv Healthc Mater*, 2025.
36. TuNa-AI Consortium. TuNa-AI: a hybrid kernel machine to design tunable nanoparticles for drug delivery. *ACS Nano*, 2025
37. Kapoor DU, Sharma JB, Gandhi SM. AI-driven design and optimization of nanoparticle-based drug delivery systems. *Sci Eng Health Stud*, 2024; 18: 1–13.
38. Sezer Karnak E, Ulucan Karnak F, Akgöl S. Green carbon dots in the era of AI: sustainable synthesis, intelligent drug delivery, advanced diagnostics, and bioimaging. *Turk J Biol*, 2025; 49(5): 498–533.
39. Applications of green carbon dots in personalized diagnostics for precision medicine. *Int J Mol Sci*, 2025; 26(7): 2846.
40. Review of green synthesized carbon dots: applications in pharmaceutical drug sensing. *Carbon Trends*, 2025
41. Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology. *AIMS Bioeng*, 2025.
42. Artificial intelligence-based advancements in nanomedicine for cancer therapy. *Front Pharmacol*, 2025
43. Almansour A, Alqahtani M. Utilization of machine learning approach for production of optimized nanoparticles for drug delivery applications. *Sci Rep*, 2025; 15: 92725.
44. Revolutionizing drug delivery: the role of artificial intelligence in nanomedicine and precision pharma. Springer Nature, 2025.